Literature DB >> 25656347

HIV testing updates and challenges: when regulatory caution and public health imperatives collide.

Bernard M Branson1.   

Abstract

Numerous improvements in HIV testing technology led recently to the first revision of recommendations for diagnostic laboratory testing in the USA in 25 years. Developments in HIV testing continue to produce tests that identify HIV infection earlier with faster turnaround times for test results. These play an important role in identifying HIV infection during the highly infectious acute phase, which has implication for both patient management and public health interventions to control the spread of HIV. Access to these developments, however, is often delayed by the regulatory apparatus for approval and oversight of HIV testing in the USA. This article summarizes recent developments in HIV diagnostic testing technology, outlines their implications for clinical management and public health, describes current systems of regulatory oversight for HIV testing in the USA, and proposes alternatives that could expedite access to improved tests as they become available.

Entities:  

Mesh:

Year:  2015        PMID: 25656347     DOI: 10.1007/s11904-014-0251-7

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  70 in total

1.  HIV antibody screening remains indispensable for ensuring viral safety of blood components despite NAT implementation.

Authors:  Syria Laperche; Pascal Morel; Marie Deschaseaux; Françoise Bouchardeau; Gulie Alimardani; Nicolas Guillaume; Philippe Rouger; Jean-Jacques Lefrère
Journal:  Transfusion       Date:  2003-10       Impact factor: 3.157

Review 2.  Food and Drug Administration regulation of in vitro diagnostic devices.

Authors:  Elizabeth Mansfield; Timothy J O'Leary; Steven I Gutman
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

3.  Expansion of HIV screening to non-clinical venues is aided by the use of dried blood spots for Western blot confirmation.

Authors:  Timothy J Sullivan; Mara San Antonio-Gaddy; April Richardson-Moore; Linda M Styer; Deborah Bigelow-Saulsbery; Monica M Parker
Journal:  J Clin Virol       Date:  2013-08-14       Impact factor: 3.168

4.  Comparison of alternative interpretive criteria for the HIV-1 Western blot and results of the Multispot HIV-1/HIV-2 Rapid Test for classifying HIV-1 and HIV-2 infections.

Authors:  Muazzam Nasrullah; Steven F Ethridge; Kevin P Delaney; Laura G Wesolowski; Timothy C Granade; Joe Schwendemann; Robert D Boromisa; James D Heffelfinger; S Michele Owen; Bernard M Branson
Journal:  J Clin Virol       Date:  2011-10-12       Impact factor: 3.168

5.  Comparative evaluation of Aptima HIV-1 Qualitative RNA assay performance using plasma and serum specimens from persons with established HIV-1 infection.

Authors:  Steven F Ethridge; Laura G Wesolowski; Muazzam Nasrullah; M Susan Kennedy; Kevin P Delaney; Debra Candal; S Michele Owen
Journal:  J Clin Virol       Date:  2011-10-12       Impact factor: 3.168

6.  Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors.

Authors:  A Hizi; R Tal; M Shaharabany; M J Currens; M R Boyd; S H Hughes; J B McMahon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

7.  Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting.

Authors:  Mark W Pandori; John Hackett; Brian Louie; Ana Vallari; Teri Dowling; Sally Liska; Jeffrey D Klausner
Journal:  J Clin Microbiol       Date:  2009-06-17       Impact factor: 5.948

8.  Detecting acute human immunodeficiency virus infection using 3 different screening immunoassays and nucleic acid amplification testing for human immunodeficiency virus RNA, 2006-2008.

Authors:  Pragna Patel; Duncan Mackellar; Pat Simmons; Apurva Uniyal; Kathleen Gallagher; Berry Bennett; Timothy J Sullivan; Alexis Kowalski; Monica M Parker; Marlene LaLota; Peter Kerndt; Patrick S Sullivan
Journal:  Arch Intern Med       Date:  2010-01-11

Review 9.  Systematic review of the use of dried blood spots for monitoring HIV viral load and for early infant diagnosis.

Authors:  Pieter W Smit; Kimberly A Sollis; Susan Fiscus; Nathan Ford; Marco Vitoria; Shaffiq Essajee; David Barnett; Ben Cheng; Suzanne M Crowe; Thomas Denny; Alan Landay; Wendy Stevens; Vincent Habiyambere; Joseph H Perriens; Rosanna W Peeling
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

10.  Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco.

Authors:  Christopher D Pilcher; Brian Louie; Shelley Facente; Sheila Keating; John Hackett; Ana Vallari; Chris Hall; Teri Dowling; Michael P Busch; Jeffrey D Klausner; Frederick M Hecht; Sally Liska; Mark W Pandori
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

View more
  9 in total

1.  Routine Screening for HIV Infection in Medical Care Settings: A Decade of Progress and Next Opportunities.

Authors:  Patrick S Sullivan; Michael S Lyons; Maggie Czarnogorski; Bernard M Branson
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

Review 2.  Selecting an HIV Test: A Narrative Review for Clinicians and Researchers.

Authors:  Christopher B Hurt; Julie A E Nelson; Lisa B Hightow-Weidman; William C Miller
Journal:  Sex Transm Dis       Date:  2017-12       Impact factor: 2.830

3.  An Approach to Achieving the Health Equity Goals of the National HIV/AIDS Strategy for the United States Among Racial/Ethnic Minority Communities.

Authors:  Donna Hubbard McCree; Linda Beer; Cynthia Prather; Zanetta Gant; Norma Harris; Madeline Sutton; Catlainn Sionean; Erica Dunbar; Jennifer Smith; Pascale Wortley
Journal:  Public Health Rep       Date:  2016 Jul-Aug       Impact factor: 2.792

4.  Highlights from the 2016 HIV diagnostics conference: The new landscape of HIV testing in laboratories, public health programs and clinical practice.

Authors:  Laura G Wesolowski; Monica M Parker; Kevin P Delaney; S Michele Owen
Journal:  J Clin Virol       Date:  2017-02-07       Impact factor: 3.168

5.  Low Rates of Adoption and Implementation of Rapid HIV Testing in Substance Use Disorder Treatment Programs.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Stéphane Helleringer; Lisa R Metsch
Journal:  J Subst Abuse Treat       Date:  2015-12-28

6.  Pattern and Frequency of Seroreactivity to Routinely Used Serologic Tests in Early-Treated Infants With HIV.

Authors:  Thanyawee Puthanakit; Jintanat Ananworanich; Siriwat Akapirat; Supanit Pattanachaiwit; Sasiwimol Ubolyam; Vatcharain Assawadarachai; Panadda Sawangsinth; Thidarat Jupimai; Suvaporn Anugulruengkitt; Monta Tawan; Pope Kosalaraksa; Thitiporn Borkird; Piyarat Suntarattiwong; Suparat Kanjanavanit; Mark S de Souza
Journal:  J Acquir Immune Defic Syndr       Date:  2020-03-01       Impact factor: 3.771

7.  A mixed methods study of HIV-related services in buprenorphine treatment.

Authors:  Hannah K Knudsen; Jennifer Cook; Michelle R Lofwall; Sharon L Walsh; Jamie L Studts; Jennifer R Havens
Journal:  Subst Abuse Treat Prev Policy       Date:  2017-08-16

8.  On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial.

Authors:  Jemima A Frimpong; Thomas D'Aunno; David C Perlman; Shiela M Strauss; Alissa Mallow; Diana Hernandez; Bruce R Schackman; Daniel J Feaster; Lisa R Metsch
Journal:  Trials       Date:  2016-03-03       Impact factor: 2.279

9.  Acute Infections, Cost per Infection and Turnaround Time in Three United States Hospital Laboratories Using Fourth-Generation Antigen-Antibody Human Immunodeficiency Virus Immunoassays.

Authors:  Laura G Wesolowski; Muazzam Nasrullah; Robert W Coombs; Eric Rosenberg; Steven F Ethridge; Angela B Hutchinson; Joan Dragavon; Jennifer Rychert; Frederick S Nolte; James E Madory; Barbara G Werner
Journal:  Open Forum Infect Dis       Date:  2015-12-09       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.